Kornman L, Chambers H, Nisbet D, Liebelt J. Pre-conception and antenatal screening for the fragile site on the X-chromosome.
Cochrane Database Syst Rev 2002;
2003:CD001806. [PMID:
11869607 PMCID:
PMC8407515 DOI:
10.1002/14651858.cd001806]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND
Fragile X is the most common cause of mental retardation after Down syndrome. It is the commonest inherited cause of mental retardation, and results from a dynamic mutation in a gene on the long arm of the X chromosome. Various strategies are used for prenatal screening.
OBJECTIVES
To determine whether pre-conceptual or antenatal screening for Fragile X carrier status in apparently low risk women confers any additional benefit over the existing practice of offering testing to women thought to be at increased risk.
SEARCH STRATEGY
We searched the Cochrane Pregnancy and Childbirth Group trials register (November 2001), the Cochrane Controlled Trials Register (The Cochrane Library Issue 3, 2001), MEDLINE (1980 to 2001), and reference lists of articles.
SELECTION CRITERIA
Randomised clinical trials comparing women being tested regardless of family history (intervention group) with women tested only when there is a family history of either fragile X and/or other undiagnosed mental illness/impairment (control group).
DATA COLLECTION AND ANALYSIS
Three reviewers independently assessed trial quality and extracted data.
MAIN RESULTS
No trials were included.
REVIEWER'S CONCLUSIONS
No information is available from randomised trials to indicate whether routine pre-conceptual or antenatal screening for fragile X carrier status confers any benefit over testing women thought to be at increased risk.
Collapse